The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. 2009

Sabine Yerly, and Thomas Junier, and Angèle Gayet-Ageron, and Emmanuelle Boffi El Amari, and Viktor von Wyl, and Huldrych F Günthard, and Bernard Hirschel, and Evgeny Zdobnov, and Laurent Kaiser, and
University of Geneva Medical School, Geneva's University Hospitals, Switzerland. sabine.yerly@hcuge.ch

OBJECTIVE To monitor HIV-1 transmitted drug resistance (TDR) in a well defined urban area with large access to antiretroviral therapy and to assess the potential source of infection of newly diagnosed HIV individuals. METHODS All individuals resident in Geneva, Switzerland, with a newly diagnosed HIV infection between 2000 and 2008 were screened for HIV resistance. An infection was considered as recent when the positive test followed a negative screening test within less than 1 year. Phylogenetic analyses were performed by using the maximum likelihood method on pol sequences including 1058 individuals with chronic infection living in Geneva. RESULTS Of 637 individuals with newly diagnosed HIV infection, 20% had a recent infection. Mutations associated with resistance to at least one drug class were detected in 8.5% [nucleoside reverse transcriptase inhibitors (NRTIs), 6.3%; non-nucleoside reverse transcriptase inhibitors (NNRTIs), 3.5%; protease inhibitors, 1.9%]. TDR (P-trend = 0.015) and, in particular, NNRTI resistance (P = 0.002) increased from 2000 to 2008. Phylogenetic analyses revealed that 34.9% of newly diagnosed individuals, and 52.7% of those with recent infection were linked to transmission clusters. Clusters were more frequent in individuals with TDR than in those with sensitive strains (59.3 vs. 32.6%, respectively; P < 0.0001). Moreover, 84% of newly diagnosed individuals with TDR were part of clusters composed of only newly diagnosed individuals. CONCLUSIONS Reconstruction of the HIV transmission networks using phylogenetic analysis shows that newly diagnosed HIV infections are a significant source of onward transmission, particularly of resistant strains, thus suggesting an important self-fueling mechanism for TDR.

UI MeSH Term Description Entries
D008297 Male Males
D010802 Phylogeny The relationships of groups of organisms as reflected by their genetic makeup. Community Phylogenetics,Molecular Phylogenetics,Phylogenetic Analyses,Phylogenetic Analysis,Phylogenetic Clustering,Phylogenetic Comparative Analysis,Phylogenetic Comparative Methods,Phylogenetic Distance,Phylogenetic Generalized Least Squares,Phylogenetic Groups,Phylogenetic Incongruence,Phylogenetic Inference,Phylogenetic Networks,Phylogenetic Reconstruction,Phylogenetic Relatedness,Phylogenetic Relationships,Phylogenetic Signal,Phylogenetic Structure,Phylogenetic Tree,Phylogenetic Trees,Phylogenomics,Analyse, Phylogenetic,Analysis, Phylogenetic,Analysis, Phylogenetic Comparative,Clustering, Phylogenetic,Community Phylogenetic,Comparative Analysis, Phylogenetic,Comparative Method, Phylogenetic,Distance, Phylogenetic,Group, Phylogenetic,Incongruence, Phylogenetic,Inference, Phylogenetic,Method, Phylogenetic Comparative,Molecular Phylogenetic,Network, Phylogenetic,Phylogenetic Analyse,Phylogenetic Clusterings,Phylogenetic Comparative Analyses,Phylogenetic Comparative Method,Phylogenetic Distances,Phylogenetic Group,Phylogenetic Incongruences,Phylogenetic Inferences,Phylogenetic Network,Phylogenetic Reconstructions,Phylogenetic Relatednesses,Phylogenetic Relationship,Phylogenetic Signals,Phylogenetic Structures,Phylogenetic, Community,Phylogenetic, Molecular,Phylogenies,Phylogenomic,Reconstruction, Phylogenetic,Relatedness, Phylogenetic,Relationship, Phylogenetic,Signal, Phylogenetic,Structure, Phylogenetic,Tree, Phylogenetic
D004812 Epidemiologic Methods Research techniques that focus on study designs and data gathering methods in human and animal populations. Epidemiologic Method,Epidemiological Methods,Methods, Epidemiologic,Epidemiological Method,Method, Epidemiologic,Method, Epidemiological,Methods, Epidemiological
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

Sabine Yerly, and Thomas Junier, and Angèle Gayet-Ageron, and Emmanuelle Boffi El Amari, and Viktor von Wyl, and Huldrych F Günthard, and Bernard Hirschel, and Evgeny Zdobnov, and Laurent Kaiser, and
January 2007, Przeglad epidemiologiczny,
Sabine Yerly, and Thomas Junier, and Angèle Gayet-Ageron, and Emmanuelle Boffi El Amari, and Viktor von Wyl, and Huldrych F Günthard, and Bernard Hirschel, and Evgeny Zdobnov, and Laurent Kaiser, and
January 2022, Frontiers in microbiology,
Sabine Yerly, and Thomas Junier, and Angèle Gayet-Ageron, and Emmanuelle Boffi El Amari, and Viktor von Wyl, and Huldrych F Günthard, and Bernard Hirschel, and Evgeny Zdobnov, and Laurent Kaiser, and
March 2007, The Journal of antimicrobial chemotherapy,
Sabine Yerly, and Thomas Junier, and Angèle Gayet-Ageron, and Emmanuelle Boffi El Amari, and Viktor von Wyl, and Huldrych F Günthard, and Bernard Hirschel, and Evgeny Zdobnov, and Laurent Kaiser, and
April 2009, The new microbiologica,
Sabine Yerly, and Thomas Junier, and Angèle Gayet-Ageron, and Emmanuelle Boffi El Amari, and Viktor von Wyl, and Huldrych F Günthard, and Bernard Hirschel, and Evgeny Zdobnov, and Laurent Kaiser, and
December 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Sabine Yerly, and Thomas Junier, and Angèle Gayet-Ageron, and Emmanuelle Boffi El Amari, and Viktor von Wyl, and Huldrych F Günthard, and Bernard Hirschel, and Evgeny Zdobnov, and Laurent Kaiser, and
December 2018, AIDS research and human retroviruses,
Sabine Yerly, and Thomas Junier, and Angèle Gayet-Ageron, and Emmanuelle Boffi El Amari, and Viktor von Wyl, and Huldrych F Günthard, and Bernard Hirschel, and Evgeny Zdobnov, and Laurent Kaiser, and
February 2013, AIDS research and human retroviruses,
Sabine Yerly, and Thomas Junier, and Angèle Gayet-Ageron, and Emmanuelle Boffi El Amari, and Viktor von Wyl, and Huldrych F Günthard, and Bernard Hirschel, and Evgeny Zdobnov, and Laurent Kaiser, and
February 2021, BMC infectious diseases,
Sabine Yerly, and Thomas Junier, and Angèle Gayet-Ageron, and Emmanuelle Boffi El Amari, and Viktor von Wyl, and Huldrych F Günthard, and Bernard Hirschel, and Evgeny Zdobnov, and Laurent Kaiser, and
August 2023, AIDS research and human retroviruses,
Sabine Yerly, and Thomas Junier, and Angèle Gayet-Ageron, and Emmanuelle Boffi El Amari, and Viktor von Wyl, and Huldrych F Günthard, and Bernard Hirschel, and Evgeny Zdobnov, and Laurent Kaiser, and
November 2001, AIDS (London, England),
Copied contents to your clipboard!